Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CROs Offer Promise of Innovative, Safe and Effective Drug Development, Says Frost & Sullivan

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Ability to provide complete and cost-effective solutions for pharma and biotechnology firms drives uptake of CRO services.

Pharmaceutical and biotech companies are outsourcing research in order to develop innovative products that meet the rising demand for therapeutics across a range of diseases.

The willingness of contract research organizations (CROs) to invest in facilities to conduct clinical trials is further advancing market prospects.

New analysis from Frost & Sullivan (http://www.healthcare.frost.com), Analysis of the European Contract Research Outsourcing Markets, finds that the markets earned revenues of approximately $6.07 billion in 2011 and estimates this to reach $11.54 billion in 2018. Phase III clinical trials account for the largest share of the total CRO market in Europe.

The promise of novel therapeutic options that offer enhanced efficacy and safety is underlining the appeal of CROs for the pharma and biotech industry.

CROs help support greater innovation and improvements in chemical and biological drug development. They address the urgent need for enhanced therapeutics in cardiovascular, oncology, autoimmune, central nervous system (CNS), infectious, endocrine and metabolic disease areas.

“Besides functionality, drugs are also tested for their efficacy and safety to ensure they meet the needs of patients across different ethnic groups and climatic zones,” states Frost & Sullivan Research Analyst Deepika Pramod Chopda. “The globalised nature of CROs enables them to facilitate the process of drug development for their clients.”

CROs offer complete and cost-effective solutions for pharma and biotech companies that are often challenged by high development costs and lengthy approval periods.

CROs could potentially offer services in drug development as well as clinical trials and testing. CROs currently account for nearly two-thirds of the Phase I to III trials conducted globally.

A key limitation to the seemingly inexorable march of CROs has been the ability of large pharmaceutical and biotech companies to perform R&D and clinical drug testing in-house.

“The availability of specialized research technologies, coupled with an exclusive focus on drug development and testing, will boost the chances of success for CROs and offset the benefits of in-house R&D services,” concludes Chopda.

Chopda continued, “Strengthening outsourcing partnerships and alliances with leading pharmaceutical and biotech companies through strategic long-term contracts will also support the uptake of CRO services.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Companion Diagnostics Benefit from Fewer Regulatory Barriers in Europe
Future revisions to in-vitro diagnostics laws will offset the launch of new tests, in a market expected to soar to $1,295.1 million in 2018.
Thursday, June 26, 2014
Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.
Thursday, June 19, 2014
CMOs Can Reduce Vendor Switching with Informational Marketing Efforts
Frost & Sullivan: Companies opt for CMOs offering high-quality services, confidentiality and clean regulatory track records.
Tuesday, November 26, 2013
Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
New market insight uncovers the latest technology trends and strategic approaches for biopharma CMOs.
Tuesday, October 01, 2013
Injectable Dose Formulations Highly Impact Global Pharmaceutical Contract Manufacturing Vendor Revenues
Frost & Sullivan finds several factors widening the fragmented contract manufacturing market and improving profitability.
Friday, August 30, 2013
New Applications in Drug Discovery Platforms to Fuel Advance of Stem Cells
Ethical, clinical and commercial issues to be navigated before full potential of stem cell therapies can be unleashed.
Wednesday, December 12, 2012
Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Although cost efficiency is a major factor motivating pharmaceutical and biotechnology firms to outsource research, there is an increased emphasis on expertise and capabilities with the focus being on quality management.
Monday, October 12, 2009
Scientific News
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!